Blum R - Search Results

1

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.

Wasserheit C, Frazein A, Oratz R, Sorich J, Downey A, Hochster H, Chachoua A, Wernz J, Zeleniuch-Jacquotte A, Blum R, Speyer J. Wasserheit C, et al. Among authors: blum r. J Clin Oncol. 1996 Jul;14(7):1993-9. doi: 10.1200/JCO.1996.14.7.1993. J Clin Oncol. 1996. PMID: 8683229 Clinical Trial.

2

Phase I study of the combination of alpha-2 interferon and cisplatinum.

Walsh C, Speyer JL, Wernz J, Hochster H, Grossberg H, Chachoua A, Molinaro P, Meyers M, Blum RH. Walsh C, et al. Among authors: blum rh. J Biol Response Mod. 1989 Feb;8(1):11-5. J Biol Response Mod. 1989. PMID: 2921608

3

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.

Chachoua A, Oratz R, Liebes L, Alter RS, Felice A, Peace D, Vilcek J, Blum RH. Chachoua A, et al. Among authors: blum rh. J Immunother Emphasis Tumor Immunol. 1994 Aug;16(2):132-41. doi: 10.1097/00002371-199408000-00007. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7804528 Clinical Trial.

4

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A. Hochster H, et al. Among authors: blum rh. Clin Cancer Res. 1997 Aug;3(8):1245-52. Clin Cancer Res. 1997. PMID: 9815806 Clinical Trial.

5

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor.

Walsh C, Blum RH, Oratz R, Goldenberg A, Downey A, Speyer JL. Walsh C, et al. Among authors: blum rh. J Cancer Res Clin Oncol. 1992;118(1):61-6. doi: 10.1007/BF01192313. J Cancer Res Clin Oncol. 1992. PMID: 1729261 Clinical Trial.

6

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology.

Hochster H, Green M, Liebes L, Speyer JL, Wernz J, Blum R, Muggia F. Hochster H, et al. Among authors: blum r. Cancer Chemother Pharmacol. 1990;26(4):297-300. doi: 10.1007/BF02897234. Cancer Chemother Pharmacol. 1990. PMID: 2369795

7

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.

Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM. Hochster HS, et al. Among authors: blum r. J Clin Oncol. 1985 Nov;3(11):1535-40. doi: 10.1200/JCO.1985.3.11.1535. J Clin Oncol. 1985. PMID: 2997408

8

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.

Colombo N, Speyer JL, Green M, Canetta R, Beller U, Wernz JC, Meyers M, Widman T, Blum RH, Piccart M, et al. Colombo N, et al. Among authors: blum rh. Cancer Chemother Pharmacol. 1989;23(5):323-8. doi: 10.1007/BF00292413. Cancer Chemother Pharmacol. 1989. PMID: 2650904

9

Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon.

Green MD, Speyer JL, Hochster HS, Liebes LF, Dunleavy S, Widman T, Wernz JC, Blum RH, Spiegel RJ, Muggia FM. Green MD, et al. Among authors: blum rh. Cancer Res. 1988 May 1;48(9):2574-8. Cancer Res. 1988. PMID: 3356017

10

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.

Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM. Speyer JL, et al. Among authors: blum rh. Am J Med. 1985 Apr;78(4):555-63. doi: 10.1016/0002-9343(85)90395-x. Am J Med. 1985. PMID: 3838618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

833 results

Search Page

Filters